Our Science – Madan Website
Ravi A. Madan, M.D.
Selected Publications |
 |
| 1)
Madan RA, Gulley JL, Kantoff PW. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J. 19: 50-8, 2013. [Journal] |
|
| 2)
Singh N, Madan RA, Gulley JL. Ipilimumab in prostate cancer. Expert Opin Biol Ther. 13: 303-13, 2013. [Journal] |
|
| 3)
Madan RA, Shah AA, Dahut WL. Is It Time to Reevaluate Definitive Therapy in Prostate Cancer?. J. Natl. Cancer Inst. [Epub ahead of print], 2013. [Journal] |
|
| 4)
Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int. [Epub ahead of print], 2013. [Journal] |
|
| 5)
Huen N, Pang AL, Tucker JA, Lee T, Vergati M, Jochems C, Intrivici C, Cereda V, Chan W, Rennert OM, Madan RA, Gulley JL, Schlom J, Tsang KY. Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. Int. J. Cancer. [Epub ahead of print], 2013. [Journal] |
|
| 6)
Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines. Semin. Oncol. 39: 296-304, 2012. [Journal] |
|
| 7)
Madan RA, Heery CR, Gulley JL. Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. Oncoimmunology. 1: 1167-1168, 2012. [Journal] |
|
| 8)
Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood. 120: 3030-8, 2012. [Journal] |
|
| 9)
Kim JW, Madan RA, Gulley JL. Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. Clin Genitourin Cancer. 10: 43-6, 2012. [Journal] |
|
| 10)
Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13: 501-8, 2012. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 5/6/2013.
